Stock Market News

Emcure Pharma Shares Fall 3% as 2.4% Stake Block Deal Hits Market

Emcure Pharmaceuticals’ shares declined 3 percent on Tuesday after a large block trade triggered selling pressure in early hours. Around 40.6 lakh shares, representing about 2.4 percent of the company’s equity, changed hands across two block deals on the exchanges.

The transaction is likely linked to Bain Capital’s BC Investments, which, according to earlier reports, was expected to offload up to 2 percent of its stake in the pharma major. Emcure Pharma shares were trading at Rs 1,352 around 11 am, extending the stock’s weak trend for 2025, during which it has fallen about 7.5 percent year to date.

Block Deal Details

A CNBC TV18 report on Monday indicated that BC Investments (Bain Capital) had planned to sell up to 2 percent of Emcure Pharma’s total equity through a block deal at a floor price of Rs 1,296.51 per share.
This price implied a 7 percent discount to Monday’s closing level of Rs 1,394.10 on the NSE.

The total deal value was estimated at up to Rs 493 crore, with a 90-day lock-in applicable to the shares sold. As of the end of Q2 2025, BC Asia held a 6.3 percent stake in Emcure Pharma.

Final confirmation on the seller and details of the buyers will be available once exchange disclosures are published.

Also Read: Budget May Peg FY27 Fiscal Deficit Target Modestly Lower Than 4.4%

Company’s Q2 Performance

Despite the stock volatility, Emcure Pharmaceuticals delivered a strong July–September (Q2) quarter:

  • Net profit: Rs 243 crore, up 25.1% YoY (vs Rs 194 crore last year)

  • Revenue: Rs 2,269.8 crore, up 13.4% YoY

  • EBITDA: Rs 475.4 crore, up 25% YoY

  • EBITDA margin: Improved to 21% (from 19%)

The company attributed its growth to broad-based demand across key therapeutic areas, including gynaecology, cardiovascular, HIV antivirals, pain management, and increased traction in domestic and international markets.
Momentum in the Indian formulations business and healthy demand from emerging markets through new launches and regulatory filings also supported performance.

Click here to explore:
Gift Nifty
FII DII Data
IPO

Pradeep Sangatramani

Pradeep Sangatramani, founder and CEO of NiftyTrader, is an IIM Calcutta alumnus with a background in engineering. Passionate about the stock market from early on, he spent years studying its dynamics and working in roles focused on market analysis, trading tools, and financial data. Realising the challenges traders face in accessing user-friendly tools, he built NiftyTrader to offer data-driven, easy-to-use solutions. Committed to transparency and education, Pradeep actively shares insights through articles and webinars, aiming to empower traders at all levels.

Published by
Pradeep Sangatramani

Recent Posts

Rate Cut Meets Falling Rupee: India’s Markets Enter a New Tug-of-War

India’s financial markets have entered a phase defined by conflicting forces, as the Reserve Bank…

25 minutes ago

Govt Shuts Door on FDI Limit Hike, Merger Chatter; PSU Bank Rally Now Hinges on Fundamentals

The momentum in public sector bank (PSU bank) stocks took a noticeable pause this week…

58 minutes ago

Large Trade Deal: Meesho, Aequs, Vidya Wires IPOs Enter Final Bidding Day as GMPs Surge on Strong Demand

The IPO market witnessed strong action on Friday as Meesho, Aequs, and Vidya Wires entered…

1 hour ago

ITC Hotels Shares Trade Flat as ₹3,856 Crore Block Deal Transfers 9% Equity; BAT Likely Seller

ITC Hotels witnessed one of its biggest trading sessions in recent months as a massive…

2 hours ago

RBI Cuts Repo Rate to 5.25%; Announces ₹1 Lakh Crore OMO & $5 Billion USD/INR Swap

In a major monetary policy move, the Reserve Bank of India (RBI) delivered a 25…

2 hours ago

Undervalued Rupee Could Attract Foreign Investors Back to Indian Markets, Say Brokerages

Indian Rupee Weakness Persists, but Analysts See Undervaluation Creating a Long-Term Opportunity The Indian rupee’s…

19 hours ago

This website uses cookies.